

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 10, 1996

CELLEGY PHARMACEUTICALS, INC.

-----  
(Exact name of registrant as specified in its charter)

Delaware

-----  
(State or other jurisdiction of incorporation)

0-26372  
-----  
(Commission  
File Number)

82-0429727  
-----  
(IRS Employer  
Identification  
Number)

1065 East Hillside Blvd., Suite 418, Foster City, CA 94404  
-----

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (415) 524-1600  
-----

This report on Form 8-K consists of 5 sequentially numbered pages.

ITEM 5: OTHER EVENTS.

LOSS OF NAMED EXECUTIVE OFFICERS

On July 10, 1996 Cellegy Pharmaceuticals, Inc. (the "Company") announced the deaths of William E. Bliss, its President and Chief Executive Officer, and Lionel N. Simon, Ph.D., its Vice President, Corporate Development, in an automobile accident. Dr. Carl Thornfeldt, the Company's Chairman of the Board, has been named Acting Chief Executive Officer. Dr. Thornfeldt, Dr. Denis Burger, a Director, Dr. Michael Francoeur, Vice President of Research and Development, and A. Richard Juelis, Vice President, Finance and Chief Financial Officer, will serve on a transition committee responsible for continuing the Company's corporate development and operations. The Company has also established a search committee, headed by Dr. Burger, and engaged Heidrick & Struggles, the executive recruiting firm which originally recruited Mr. Bliss, to conduct a nationwide search for a new Chief Executive Officer.

RELOCATION OF CORPORATE HEADQUARTERS

The Company has also relocated its headquarters to 1065 East Hillsdale Blvd., Suite 418, Foster City, CA 94404. Its new telephone number at that location is (415) 524-1600, and its new telephone number for facsimile transmissions is (415) 524-1616.

ITEM 7: FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

The following exhibits are filed herewith:

20.01 Press Release

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: July 25, 1996

CELLEGY PHARMACEUTICALS, INC..

By: /s/ A. Richard Juelis

-----  
A. Richard Juelis  
Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number -----	Description of Exhibit -----	Sequentially Numbered Page -----
20.01	Press Release	5

EXHIBIT 20.01

CELLEGY ANNOUNCES THE DEATHS OF TWO EXECUTIVES

NOVATO, Calif., July 11/PRNewswire/ -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY; Warrants, CLGYW) regrets to announce that its President and Chief Executive Officer, William E. Bliss, and its Vice President of Corporate Development, Lionel D. Simon, Ph.D., were killed in an automobile accident while traveling home together on Tuesday evening, July 9, 1996.

Carl R. Thornfeldt, M.D., Chairman of the Board and founder of Cellegy, has assumed the position of acting CEO pending recruitment of a replacement for Mr. Bliss.

Cellegy's Board of Directors met yesterday to establish a transition committee responsible for continuity of the Company's business strategy, business development and operations. Chaired by Dr. Thornfeldt, the committee includes Richard Juelis, Vice President, Finance and Chief Financial Officer; Dr. Michael Francoeur, Vice President, Research and Development; and Denis R. Burger, Ph.D., a board member. Mr. Juelis will be responsible for Cellegy's administrative and investor relations activities, while Dr. Francoeur will be responsible for the Company's research and technical development activities. Both men have senior management experience in the pharmaceutical industry.

Cellegy also established a committee whose primary responsibility will be to recruit a new CEO. This committee will be chaired by Dr. Burger, who is an executive officer at three other biomedical companies. Heidrich & Struggles, the executive recruiting firm that originally recruited Mr. Bliss, will also assist in the search. "We are deeply saddened by the loss of William Bliss and Lionel Simon," said Dr. Thornfeldt. "On behalf of myself, the Board of Directors and the employees of Cellegy, we offer our deepest sympathies to their families."

"Since joining Cellegy, Bill and Lionel had made outstanding contributions that moved the Company to new height. These included building a strong management team and board group and aggressively pursuing key corporate relationships and licensing agreements. Thanks to these activities, we are confident Cellegy will be able to meet its goals in research and business development programs in the months and years to come."

Cellegy is a pharmaceutical company engaged in the development, through corporate collaborations and marketing arrangements, of innovative drug delivery products as well as consumer and prescription products for the skin.

-0-

/CONTACT: Richard Juelis, Chief Financial Officer of Cellegy Pharmaceuticals, Inc., 415-382-6770, or Jimmy Caplan of Market Makers, 805-569-0076, or Rick Eisenberg of Eisenberg Communications, 212-496-6828/ (CLGY)